Status:
COMPLETED
Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia
Lead Sponsor:
Prince of Songkla University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Patients With Febrile Neutropenia
Eligibility:
All Genders
20-90 years
Phase:
PHASE4
Brief Summary
This is prospective and randomized study to compare the pharmacodynamics (t\>MIC) of 0.5 g every 6 h of imipenem in twelve patients with febrile neutropenia following administration by a 4 h infusion ...
Eligibility Criteria
Inclusion
- Patients aged \> or = 20 years
- Patients who have febrile neutropenia with Gram negative bacilli infections which are sensitive to imipenem by the disk diffusion
- Patients who are likely to survive 3 days
Exclusion
- Patients who have documented hypersensitivity to imipenem or other carbapenems
- Patients who have an estimated creatinine clearance of \< 50 ml/min
- Patients who are in circulatory shock or hypotension (systolic \< 90 mmHg)
- Patients who are pregnant
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT02213783
Start Date
February 1 2011
End Date
September 1 2013
Last Update
August 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University
Hat Yai, Changwat Songkhla, Thailand, 90110